{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:13:21Z","timestamp":1789514001045,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Progress toward the global target for 95% virological suppression among those on antiretroviral treatment (ART) is still suboptimal. We describe the viral load (VL) cascade, the incidence of virological failure and associated risk factors among people living with HIV receiving first-line ART in an HIV cohort in Myanmar treated by the M\u00e9decins Sans Fronti\u00e8res in collaboration with the Ministry of Health and Sports Myanmar.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective cohort study, including adult patients with at least one HIV viral load test result and having received of at least 6\u00a0months\u2019 standard first-line ART. The incidence rate of virological failure (HIV viral load\u2009\u2265\u20091000 copies\/mL) was calculated. Multivariable Cox\u2019s regression was performed to identify risk factors for virological failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 25,260 patients with a median age of 33.1\u00a0years (interquartile range, IQR 28.0\u201339.1) and a median observation time of 5.4\u00a0years (IQR 3.7\u20137.9). Virological failure was documented in 3,579 (14.2%) participants, resulting in an overall incidence rate for failure of 2.5 per 100 person-years of follow-up. Among those who had a follow-up viral load result, 1,258 (57.1%) had confirmed virological failure, of which 836 (66.5%) were switched to second-line treatment. An increased hazard for failure was associated with age\u2009\u2264\u200919\u00a0years (adjusted hazard ratio, aHR 1.51; 95% confidence intervals, CI 1.20\u20131.89; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), baseline tuberculosis (aHR 1.39; 95% CI 1.14\u20131.49; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), a history of low-level viremia (aHR 1.60; 95% CI 1.42\u20131.81; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), or a history of loss-to-follow-up (aHR 1.24; 95% CI 1.41\u20131.52; <jats:italic>p<\/jats:italic>\u2009=\u20090.041) and being on the same regimen (aHR 1.37; 95% CI 1.07\u20131.76; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Cumulative appointment delay was not significantly associated with failure after controlling for covariates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>VL monitoring is an important tool to improve programme outcomes, however limited coverage of VL testing and acting on test results hampers its full potential. In our cohort children and adolescents, PLHIV with history of loss-to-follow-up or those with low-viremia are at the highest risk of virological failure and might require more frequent virological monitoring than is currently recommended.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-021-00336-0","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T08:05:36Z","timestamp":1618992336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Predictors of virological failure among people living with HIV receiving first line antiretroviral treatment in Myanmar: retrospective cohort analysis"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7541-6380","authenticated-orcid":false,"given":"Anita","family":"Mesic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Htay Thet","family":"Mar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phone","family":"Thit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Decroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Lenglet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moe Pyae","family":"Thandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thin Thin","family":"Thwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung Aung","family":"Kyaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Homan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Sangma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Grieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Piriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koert","family":"Ritmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefien","family":"Van Olmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutgarde","family":"Lynen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Htun Nyunt","family":"Oo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"336_CR1","unstructured":"UNAIDS. Fast Track Strategy to end the AIDS epidemic by 2030. [Internet]. 2014. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/JC2686_WAD2014report_en.pdf. Accessed 20 Jul 2020."},{"key":"336_CR2","unstructured":"UNAIDS. UNAIDS Data 2019. [Internet]. 2019. https:\/\/www.unaids.org\/en\/resources\/documents\/2019\/2019-UNAIDS-data. Accessed 30 Jul 2020."},{"issue":"8","key":"336_CR3","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/cid\/ciw001","volume":"62","author":"T Roberts","year":"2016","unstructured":"Roberts T, Cohn J, Bonner K, Hargreaves S. Scale-up of routine viral load testing in resource-poor settings: current and future implementation challenges. Clin Infect Dis. 2016;62(8):1043\u20138.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"336_CR4","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1016\/S2352-3018(15)00087-9","volume":"2","author":"AD Haas","year":"2015","unstructured":"Haas AD, Keiser O, Balestre E, Brown S, Bissagnene E, Chimbetete C, et al. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis. The lancet HIV. 2015;2(7):e271\u20138.","journal-title":"The lancet HIV"},{"issue":"2","key":"336_CR5","doi-asserted-by":"publisher","first-page":"e0171780","DOI":"10.1371\/journal.pone.0171780","volume":"12","author":"NTT Kyaw","year":"2017","unstructured":"Kyaw NTT, Harries AD, Kumar AMV, Oo MM, Kyaw KWY, Win T, et al. High rate of virological failure and low rate of switching to second-line treatment among adolescents and adults living with HIV on first-line ART in Myanmar, 2005\u20132015. PLoS ONE. 2017;12(2):e0171780.","journal-title":"PLoS ONE"},{"issue":"1","key":"336_CR6","first-page":"696","volume":"18","author":"D Narainsamy","year":"2017","unstructured":"Narainsamy D, Mahomed S. Delays in switching patients onto second-line antiretroviral treatment at a public hospital in eThekwini, KwaZulu-Natal. South\u00a0Afr J\u00a0HIV\u00a0Med. 2017;18(1):696.","journal-title":"South\u00a0Afr J\u00a0HIV\u00a0Med"},{"key":"336_CR7","unstructured":"M\u00e9decins Sans Fronti\u00e8res. Untangling the web of antiretroviral price reductions. [Internet]. 2016. https:\/\/msfaccess.org\/untangling-web-antiretroviral-price-reductions-18th-edition. Accessed 30 Jul 2020."},{"issue":"1","key":"336_CR8","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1186\/s12879-017-2680-6","volume":"17","author":"V Ssempijja","year":"2017","unstructured":"Ssempijja V, Nakigozi G, Chang L, Gray R, Wawer M, Ndyanabo A, et al. Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda. BMC Infect Dis. 2017;17(1):582.","journal-title":"BMC Infect Dis"},{"issue":"17","key":"336_CR9","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1097\/QAD.0000000000001964","volume":"32","author":"R Kantor","year":"2018","unstructured":"Kantor R, DeLong A, Schreier L, Reitsma M, Kemboi E, Orido M, et al. HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya. AIDS (London, England). 2018;32(17):2485\u201396.","journal-title":"AIDS (London, England)"},{"key":"336_CR10","unstructured":"National AIDS Programme Ministry of Health and Sports Myanmar. Myanmar Integrated Biological and Behavioural Surveillance Survey & Populaion Size Estimates among People Who Inject Drugs (PWID) 2017\u20132018. [Internet]. 2018. https:\/\/www.aidsdatahub.org\/sites\/default\/files\/resource\/myanmar-ibbs-and-population-size-estimates-among-pwid-2017-2018.pdf. Accessed 20 Jul 2020."},{"key":"336_CR11","volume-title":"Annual progress report 2019","author":"National AIDS Programme Ministry of Health and Sports Myanmar","year":"2020","unstructured":"National AIDS Programme Ministry of Health and Sports Myanmar. Annual progress report 2019. Naypithaw: Ministry of Health and Sports; 2020."},{"issue":"321","key":"336_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/oxfordjournals.afraf.a097364","volume":"80","author":"H Dinwiddy","year":"1981","unstructured":"Dinwiddy H. The search for unity in Uganda\u2014early days to 1966. Afr Affairs. 1981;80(321):501\u201318.","journal-title":"Afr Affairs"},{"issue":"2 Suppl 1","key":"336_CR13","doi-asserted-by":"publisher","first-page":"19393","DOI":"10.7448\/IAS.18.2.19393","volume":"18","author":"P Lall","year":"2015","unstructured":"Lall P, Lim SH, Khairuddin N, Kamarulzaman A. Review: an urgent need for research on factors impacting adherence to and retention in care among HIV-positive youth and adolescents from key populations. J Int AIDS Soc. 2015;18(2 Suppl 1):19393.","journal-title":"J Int AIDS Soc"},{"key":"336_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s41256-019-0120-4","volume":"4","author":"MA Assemie","year":"2019","unstructured":"Assemie MA, Alene M, Ketema DB, Mulatu S. Treatment failure and associated factors among first line patients on highly active antiretroviral therapy in Ethiopia: a systematic review and meta-analysis. Glob Health Res Policy. 2019;4:32.","journal-title":"Glob Health Res Policy"},{"issue":"2","key":"336_CR15","doi-asserted-by":"publisher","first-page":"e0211344","DOI":"10.1371\/journal.pone.0211344","volume":"14","author":"F Kiweewa","year":"2019","unstructured":"Kiweewa F, Esber A, Musingye E, Reed D, Crowell TA, Cham F, et al. HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study. PLoS ONE. 2019;14(2):e0211344.","journal-title":"PLoS ONE"},{"issue":"9","key":"336_CR16","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1093\/jac\/dkv143","volume":"70","author":"M Rup\u00e9rez","year":"2015","unstructured":"Rup\u00e9rez M, Pou C, Maculuve S, Cede\u00f1o S, Luis L, Rodr\u00edguez J, et al. Determinants of virological failure and antiretroviral drug resistance in Mozambique. J Antimicrob Chemother. 2015;70(9):2639\u201347.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"336_CR17","doi-asserted-by":"publisher","first-page":"e0116144","DOI":"10.1371\/journal.pone.0116144","volume":"10","author":"K Jobanputra","year":"2015","unstructured":"Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B, et al. Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. PLoS ONE. 2015;10(2):e0116144.","journal-title":"PLoS ONE"},{"issue":"7","key":"336_CR18","doi-asserted-by":"publisher","first-page":"e0200505","DOI":"10.1371\/journal.pone.0200505","volume":"13","author":"NF Telele","year":"2018","unstructured":"Telele NF, Kalu AW, Marrone G, Gebre-Selassie S, Fekade D, Tegbaru B, et al. Baseline predictors of antiretroviral treatment failure and lost to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia. PLoS ONE. 2018;13(7):e0200505.","journal-title":"PLoS ONE"},{"issue":"2","key":"336_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S1473-3099(17)30681-3","volume":"18","author":"LE Hermans","year":"2018","unstructured":"Hermans LE, Moorhouse M, Carmona S, Grobbee DE, Hofstra LM, Richman DD, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. Lancet Infect Dis. 2018;18(2):188\u201397.","journal-title":"Lancet Infect Dis"},{"key":"336_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa413","author":"O Elvstam","year":"2020","unstructured":"Elvstam O, Marrone G, Medstrand P, Treutiger CJ, Sonnerborg A, Gisslen M, et al. All-cause mortality and serious non-AIDS events in adults with low-level HIV viremia during combination antiretroviral therapy: results from a swedish nationwide observational study. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa413.","journal-title":"Clin Infect Dis."},{"issue":"11","key":"336_CR21","doi-asserted-by":"publisher","first-page":"e1002407","DOI":"10.1371\/journal.pmed.1002407","volume":"14","author":"SR Kaplan","year":"2017","unstructured":"Kaplan SR, Oosthuizen C, Stinson K, Little F, Euvrard J, Schomaker M, et al. Contemporary disengagement from antiretroviral therapy in Khayelitsha, South Africa: a cohort study. PLoS Med. 2017;14(11):e1002407.","journal-title":"PLoS Med"},{"issue":"2","key":"336_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/inthealth\/ihz049","volume":"12","author":"P Yonga","year":"2020","unstructured":"Yonga P, Kalya S, Lynen L, Decroo T. Temporary disengagement and re-engagement in human immunodeficiency virus care in a rural county serving pastoralist communities in Kenya: a retrospective cohort study. Int Health. 2020;12(2):95\u2013100.","journal-title":"Int Health"},{"key":"336_CR23","first-page":"63","volume":"2013","author":"E Mills","year":"1999","unstructured":"Mills E, Funk A, Kanters S, Kawuma E, Cooper C, Mukasa B, et al. Long-term health care interruptions among HIV-positive patients in Uganda. J Acquir Immune Defic Syndr. 1999;2013:63.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"336_CR24","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/QAD.0000000000001373","volume":"31","author":"CA Sabin","year":"2017","unstructured":"Sabin CA, Howarth A, Jose S, Hill T, Apea V, Morris S, et al. Association between engagement in-care and mortality in HIV-positive persons. AIDS (London, England). 2017;31(5):653\u201360.","journal-title":"AIDS (London, England)"},{"key":"336_CR25","doi-asserted-by":"publisher","DOI":"10.4172\/2155-6113.1000543","author":"RM Grimes","year":"2016","unstructured":"Grimes RM, Hallmark CJ, Watkins KL, Agarwal S, McNeese ML. Re-engagement in HIV care: a clinical and public health priority. J AIDS Clin Res. 2016. https:\/\/doi.org\/10.4172\/2155-6113.1000543.","journal-title":"J AIDS Clin Res."},{"key":"336_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1139","author":"N Ford","year":"2018","unstructured":"Ford N, Meintjes G, Calmy A, Bygrave H, Migone C, Vitoria M, et al. Managing advanced HIV disease in a public health approach. Clin Infect Dis. 2018. https:\/\/doi.org\/10.1093\/cid\/cix1139.","journal-title":"Clin Infect Dis."},{"issue":"suppl 2","key":"336_CR27","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1093\/cid\/cix1140","volume":"66","author":"M Osler","year":"2018","unstructured":"Osler M, Hilderbrand K, Goemaere E, Ford N, Smith M, Meintjes G, et al. The continuing burden of advanced HIV disease over 10 years of increasing antiretroviral therapy coverage in South Africa. Clin Infect Dis. 2018;66(suppl 2):S118\u201325.","journal-title":"Clin Infect Dis."},{"issue":"4","key":"336_CR28","doi-asserted-by":"publisher","first-page":"e0214739","DOI":"10.1371\/journal.pone.0214739","volume":"14","author":"S Blankley","year":"2019","unstructured":"Blankley S, Gashu T, Ahmad B, Belaye AK, Ringtho L, Mesic A, et al. Lessons learned: Retrospective assessment of outcomes and management of patients with advanced HIV disease in a semi-urban polyclinic in Epworth, Zimbabwe. PLoS ONE. 2019;14(4):e0214739.","journal-title":"PLoS ONE"},{"issue":"2","key":"336_CR29","doi-asserted-by":"publisher","first-page":"17375","DOI":"10.7448\/IAS.15.2.17375","volume":"15","author":"M Charles","year":"2012","unstructured":"Charles M, Leger PD, Severe P, Guiteau C, Apollon A, Gulick RM, et al. Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti. J Int AIDS Soc. 2012;15(2):17375.","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"336_CR30","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1086\/649215","volume":"50","author":"Y Ma","year":"2010","unstructured":"Ma Y, Zhao D, Yu L, Bulterys M, Robinson ML, Zhao Y, et al. Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis. 2010;50(2):264\u201371.","journal-title":"Clin Infect Dis"},{"key":"336_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32828cc8b7","author":"L Ferradini","year":"2007","unstructured":"Ferradini L, Laureillard D, Prak N, Ngeth C, Fernandez M, Pinoges L, et al. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS. 2007. https:\/\/doi.org\/10.1097\/QAD.0b013e32828cc8b7.","journal-title":"AIDS"},{"key":"336_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182557785","author":"MP Fox","year":"2012","unstructured":"Fox MP, Cutsem GV, Giddy J, Maskew M, Keiser O, Prozesky H, et al. Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa. JAIDS. 2012. https:\/\/doi.org\/10.1097\/QAI.0b013e3182557785.","journal-title":"JAIDS"},{"issue":"2","key":"336_CR33","doi-asserted-by":"publisher","first-page":"e0191695","DOI":"10.1371\/journal.pone.0191695","volume":"13","author":"EH Berm\u00fadez-Aza","year":"2018","unstructured":"Berm\u00fadez-Aza EH, Shetty S, Ousley J, Kyaw NTT, Soe TT, Soe K, et al. Long-term clinical, immunological and virological outcomes of patients on antiretroviral therapy in southern Myanmar. PLoS ONE. 2018;13(2):e0191695.","journal-title":"PLoS ONE"},{"issue":"9","key":"336_CR34","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/cid\/civ556","volume":"61","author":"TS Boender","year":"2015","unstructured":"Boender TS, Sigaloff KC, McMahon JH, Kiertiburanakul S, Jordan MR, Barcarolo J, et al. Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis. 2015;61(9):1453\u201361.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"336_CR35","doi-asserted-by":"publisher","first-page":"21930","DOI":"10.7448\/IAS.20.1.21930","volume":"20","author":"RS Boerma","year":"2017","unstructured":"Boerma RS, Bunupuradah T, Dow D, Fokam J, Kariminia A, Lehman D, et al. Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure. J Int AIDS Soc. 2017;20(1):21930.","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"336_CR36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jac\/dkw463","volume":"72","author":"RS Boerma","year":"2016","unstructured":"Boerma RS, Sigaloff KCE, Akanmu AS, Inzaule S, van Boele Hensbroek M, de Rinke Wit TF, et al. Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis. J Antimicrob Chemother. 2016;72(2):365\u201371.","journal-title":"J Antimicrob Chemother."},{"issue":"1","key":"336_CR37","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/s12879-018-3372-6","volume":"18","author":"Z Sithole","year":"2018","unstructured":"Sithole Z, Mbizvo E, Chonzi P, Mungati M, Juru TP, Shambira G, et al. Virological failure among adolescents on ART, Harare City, 2017- a case-control study. BMC Infect Dis. 2018;18(1):469.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"336_CR38","first-page":"428","volume":"60","author":"MP Fox","year":"2012","unstructured":"Fox MP, Cutsem GV, Giddy J, Maskew M, Keiser O, Prozesky H, et al. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. JAIDS. 2012;60(4):428\u201337.","journal-title":"JAIDS"},{"issue":"1","key":"336_CR39","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1186\/s12879-019-4651-6","volume":"19","author":"D Mulisa","year":"2019","unstructured":"Mulisa D, Tesfa M, Mullu Kassa G, Tolossa T. Determinants of first line antiretroviral therapy treatment failure among adult patients on ART at central Ethiopia: un-matched case control study. BMC Infect Dis. 2019;19(1):1024.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"336_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1742-6405-8-42","volume":"8","author":"N Khienprasit","year":"2011","unstructured":"Khienprasit N, Chaiwarith R, Sirisanthana T, Supparatpinyo K. Incidence and risk factors of antiretroviral treatment failure in treatment-na\u00efve HIV-infected patients at Chiang Mai University Hospital, Thailand. AIDS Res Ther. 2011;8(1):42.","journal-title":"AIDS Res Ther"},{"key":"336_CR41","unstructured":"World Health Organization. Consolidated Guideline on The Use of Antiretroviral Drugs For Treating and Preventing HIV Infection. [Internet]. 2016. https:\/\/www.who.int\/publications\/guidelines\/hiv_aids\/en\/. Accessed 25 Jul 2020."},{"issue":"10","key":"336_CR42","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1097\/QAD.0000000000002234","volume":"33","author":"A Shroufi","year":"2019","unstructured":"Shroufi A, Van Cutsem G, Cambiano V, Bansi-Matharu L, Duncan K, Murphy RA, et al. Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure. AIDS (London, England). 2019;33(10):1635\u201344.","journal-title":"AIDS (London, England)"},{"key":"336_CR43","unstructured":"World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. [Internet]. 2010. https:\/\/www.who.int\/publications\/guidelines\/hiv_aids\/en\/. Accessed 25 Jul 2020."},{"key":"336_CR44","unstructured":"World Health Organization. Consolidated Guidelines on The Use Of Antiretroviral Drugs for Treating and Preventing HIV Infection. [Internet]. 2013. https:\/\/www.who.int\/publications\/guidelines\/hiv_aids\/en\/. Accessed 25 Jul 2020."},{"issue":"10","key":"336_CR45","doi-asserted-by":"publisher","first-page":"e25194","DOI":"10.1002\/jia2.25194","volume":"21","author":"D Etoori","year":"2018","unstructured":"Etoori D, Ciglenecki I, Ndlangamandla M, Edwards CG, Jobanputra K, Pasipamire M, et al. Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy adherence and rationalize second-line switches in Swaziland. J Int AIDS Soc. 2018;21(10):e25194.","journal-title":"J Int AIDS Soc"},{"issue":"8","key":"336_CR46","doi-asserted-by":"publisher","first-page":"e0220337","DOI":"10.1371\/journal.pone.0220337","volume":"14","author":"TR Glass","year":"2019","unstructured":"Glass TR, Motaboli L, Nsakala B, Lerotholi M, Vanobberghen F, Amstutz A, et al. The viral load monitoring cascade in a resource-limited setting: a prospective multicentre cohort study after introduction of routine viral load monitoring in rural Lesotho. PLoS ONE. 2019;14(8):e0220337.","journal-title":"PLoS ONE"},{"key":"336_CR47","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000349","author":"ML Petersen","year":"2014","unstructured":"Petersen ML, Tran L, Geng EH, Reynolds SJ, Kambugu A, Wood R, et al. Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa. AIDS. 2014. https:\/\/doi.org\/10.1097\/QAD.0000000000000349.","journal-title":"AIDS"},{"issue":"11","key":"336_CR48","doi-asserted-by":"publisher","first-page":"e25415","DOI":"10.1002\/jia2.25415","volume":"22","author":"N Ford","year":"2019","unstructured":"Ford N, Orrell C, Shubber Z, Apollo T, Vojnov L. HIV viral resuppression following an elevated viral load: a systematic review and meta-analysis. J Int AIDS Soc. 2019;22(11):e25415.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"336_CR49","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/QAI.0000000000002313","volume":"84","author":"H Bell Gorrod","year":"2020","unstructured":"Bell Gorrod H, Court R, Schomaker M, Maartens G, Murphy RA. Increased mortality with delayed and missed switch to second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2020;84(1):107\u201313.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"336_CR50","doi-asserted-by":"publisher","first-page":"e0161469","DOI":"10.1371\/journal.pone.0161469","volume":"11","author":"JK Rohr","year":"2016","unstructured":"Rohr JK, Ive P, Horsburgh CR, Berhanu R, Shearer K, Maskew M, et al. Marginal structural models to assess delays in second-line HIV treatment initiation in South Africa. PLoS ONE. 2016;11(8):e0161469.","journal-title":"PLoS ONE"},{"issue":"4","key":"336_CR51","doi-asserted-by":"publisher","first-page":"e0215236","DOI":"10.1371\/journal.pone.0215236","volume":"14","author":"E Venables","year":"2019","unstructured":"Venables E, Ndlovu Z, Munyaradzi D, Mart\u00ednez-P\u00e9rez G, Mbofana E, Nyika P, et al. Patient and health-care worker experiences of an HIV viral load intervention using SMS: a qualitative study. PLoS ONE. 2019;14(4):e0215236.","journal-title":"PLoS ONE"},{"issue":"4","key":"336_CR52","doi-asserted-by":"publisher","first-page":"225","DOI":"10.5588\/pha.18.0063","volume":"8","author":"H Sunpath","year":"2018","unstructured":"Sunpath H, Hatlen TJ, Naidu KK, Msimango P, Adams RN, Moosa MS, et al. Targeting the third \u201c90\u201d: introducing the viral load champion. Public Health Action. 2018;8(4):225\u201331.","journal-title":"Public Health Action"},{"issue":"13","key":"336_CR53","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1097\/QAD.0000000000002306","volume":"33","author":"J Fleming","year":"2019","unstructured":"Fleming J, Mathews WC, Rutstein RM, Aberg J, Somboonwit C, Cheever LW, et al. Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy. AIDS. 2019;33(13):2005\u201312.","journal-title":"AIDS"},{"issue":"1","key":"336_CR54","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12879-020-4837-y","volume":"20","author":"T Zhang","year":"2020","unstructured":"Zhang T, Ding H, An M, Wang X, Tian W, Zhao B, et al. Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort. BMC Infect Dis. 2020;20(1):147.","journal-title":"BMC Infect Dis"},{"key":"336_CR55","unstructured":"M\u00e9decins Sans Fronti\u00e8res. MSF Ethics Review Board Standard Operating Procedures. [Internet]. 2013. https:\/\/fieldresearch.msf.org\/handle\/10144\/294968. Accessed 25 Jul 2020."}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-021-00336-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-021-00336-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-021-00336-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T08:10:12Z","timestamp":1618992612000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-021-00336-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["336"],"URL":"https:\/\/doi.org\/10.1186\/s12981-021-00336-0","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,21]]},"assertion":[{"value":"9 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board, Department of Medical Research, Ministry of Health and Sports, Myanmar (Ethics\/DMR\/2019\/153) and fulfilled the exemption criteria set by the MSF independent Ethical Review Board [] for a posteriori analyses of routinely collected clinical data and thus did not require MSF ERB review. It was conducted with a permission from the MSF Medical Director, Operational Center Amsterdam. Exemption from review by the MSF ERB for retrospective analyses of routinely collected data requires consent to have been given by patients in MSF programmes at the time of treatment for secondary use of their data. Therefore, consents of individuals for secondary analysis of the dataset was not sought.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Authors have no competing interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}